A Phase Ib/II Study of APG-2575 in Combination With Azacitidine in Patients With Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia (MPAL), Chronic Myelomonocytic Leukemia (CMML) and Higher-Risk Myelodysplastic Syndrome (MDS)
Latest Information Update: 16 Dec 2024
Price :
$35 *
At a glance
- Drugs Azacitidine (Primary) ; Lisaftoclax (Primary)
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; B-cell leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; T-cell leukaemia
- Focus Adverse reactions
- Sponsors Ascentage Pharma
- 10 Dec 2024 According to an Ascentage Pharma media release, data from this study will be presented in a Poster Presentation at the 66th American Society of Hematology (ASH) Annual Meeting, taking place in San Diego, CA, the United States.
- 23 May 2024 According to an Ascentage Pharma media release, data from this study will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place on May 31-June 4, 2024 in Chicago, IL.
- 23 May 2024 Results presented in an Ascentage Pharma Media Release.